Sputnik Light

Human Ad26 Adenovirus Vector Platform

Human Ad26 Adenovirus Vector Platform

Vaccine retains key characteristics of Sputnik V two-shot vaccine including strong cellular and humoral immunogenicity and safe profile
Given strong results of safety and efficacy trials with Sputnik V, the Ad26 mono vaccine – Sputnik Light – it is likely to provide sufficient protection to prevent COVID-19 disease
Efficacy clinical trials are underway to prove COVID-19 protection and to confirm expected Targeted Product Profile (TPP)
In populations who elicit stronger immune response (e.g. younger people) Sputnik Light as a mono vaccine will provide efficacy without the need for the second booster shot
One shot only vaccine with easy logistics and distribution will result in faster execution that may be critical for population immunity

Vector creation

  • A vector is a virus that lacks a gene responsible for reproduction and is used to transport genetic material from another virus that is being vaccinated against into cell
  • A gene coding S-protein of SARS-COV-2 spikes is inserted into vector Ad26

Vaccination with effective mono-vaccine

  • Vector (Ad 26) with a gene coding S-protein of coronavirus gets into cell
  • As cell synthesizes S-protein, the development of immunity begins

Phase I/II Safety and Immunogenicity Stud

Design
A Phase 1/2 Open Label Trial to Evaluate Safety, Tolerability and Immunogenicity of the Sputnik Light Vector Vaccine in Prophylactic Treatment for SARS-СoV-2 Infection
Age group: 18 and older
Number of subjects: 110, enrollment has been completed
Countries: Russian Federation only
Start Date: Jan 2021
Interim Analysis Date: first week of March 2021

Phase III Efficacy Study

Design
A Phase 3, Randomized, double-blind, placebo-controlled, International trial to evaluate Efficacy, Immunogenicity, Safety and Tolerability of the Sputnik Light Vector Vaccine in prophylactic Treatment for SARS-СoV-2 infection
Age group: 18 and older
Number of subjects: 6000 – 7000
Countries:
United Arab Emirates , Russian Federation
Expected start date: Feb 2021
Expected Interim Analysis Date (efficacy): May 2021